TR200000673T2 - FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. - Google Patents

FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.

Info

Publication number
TR200000673T2
TR200000673T2 TR2000/00673T TR200000673T TR200000673T2 TR 200000673 T2 TR200000673 T2 TR 200000673T2 TR 2000/00673 T TR2000/00673 T TR 2000/00673T TR 200000673 T TR200000673 T TR 200000673T TR 200000673 T2 TR200000673 T2 TR 200000673T2
Authority
TR
Turkey
Prior art keywords
compounds
formula
agonists
aromatic
substituted tetrahydro
Prior art date
Application number
TR2000/00673T
Other languages
English (en)
Inventor
Anthony Delong Mitchell
August Wos John
Jack S. Amburgey, Jr.
De Biswanath
George Dai Haiyan
Lindsey Soper David
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Publication of TR200000673T2 publication Critical patent/TR200000673T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

(Formül(I));Bulus yeni PGF analoglari sunmaktadir. Özellikle bu bulus bir formül (I) yapisini haiz bilesiklere iliskindir: R1,R2;R3,R4, X ve Z tanimlandigi gibidir. Bu bulus ayrica adi geçen formülün optik izomerlerini, diastereomerlerini ve enantiomerlerini ve farmasötik olarak kabul edilebilir tuzlarini, biyohidrolize edilebilir amitlerini, esterlerini ve imitlerini kapsamaktadir. Bu bulusun bilesikleri kemik bozukluklari ve glokom gibi çesitli hastaliklarin ve durumlarin tedavisi için yararlidir. Bu nedenle bulus ayrica bu bilesikleri içeren farmasötik bilesimleri sunmaktadir. Bulus ayrica bu bilesikleri veya bunlari içeren bilesimleri kullanarak kemik bozukluklarini ve glokomu tedavi etmek için yöntemler sunmaktadir.
TR2000/00673T 1997-09-09 1998-09-04 FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler. TR200000673T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5825297P 1997-09-09 1997-09-09

Publications (1)

Publication Number Publication Date
TR200000673T2 true TR200000673T2 (tr) 2000-11-21

Family

ID=22015635

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00673T TR200000673T2 (tr) 1997-09-09 1998-09-04 FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.

Country Status (24)

Country Link
US (1) US6048895A (tr)
EP (1) EP1012137B1 (tr)
JP (2) JP4619531B2 (tr)
KR (1) KR20010023838A (tr)
CN (1) CN1269784A (tr)
AR (1) AR017078A1 (tr)
AT (1) ATE227266T1 (tr)
AU (1) AU731032B2 (tr)
BR (1) BR9812631A (tr)
CA (1) CA2303801C (tr)
CO (1) CO4970733A1 (tr)
DE (1) DE69809268T2 (tr)
DK (1) DK1012137T3 (tr)
HU (1) HUP0004427A3 (tr)
ID (1) ID24845A (tr)
IL (1) IL134840A0 (tr)
NO (1) NO20001139L (tr)
NZ (1) NZ503738A (tr)
PE (1) PE123099A1 (tr)
PL (1) PL339221A1 (tr)
SK (1) SK3382000A3 (tr)
TR (1) TR200000673T2 (tr)
WO (1) WO1999012898A1 (tr)
ZA (1) ZA988232B (tr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
DE69809268T2 (de) * 1997-09-09 2003-08-28 The Procter & Gamble Co., Cincinnati Aromatische c16-c20-substituierte tetrahydro-prostaglandine und ihre verwendung als prostaglandin f agonisten
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
CA2380326C (en) 1999-08-04 2008-03-18 The Procter & Gamble Company Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
KR100437873B1 (ko) * 2001-05-08 2004-06-26 연성정밀화학(주) 프로스타글란딘 유도체의 제조방법 및 그의 입체특이적출발물질
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
EP1812017A2 (en) * 2004-10-21 2007-08-01 Duke University Ophthamological drugs
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
KR20100099145A (ko) * 2007-10-31 2010-09-10 파멜라 립킨 프로스타글란딘 유사체 조성물 및 상피 관련 질환을 치료하는 방법
US20100074857A1 (en) * 2008-09-23 2010-03-25 Pamela Lipkin Compositions and methods to treat epithelial-related conditions
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
EP2349242B1 (en) 2008-10-29 2018-12-05 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
CA2760562C (en) 2009-05-01 2016-07-19 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
CN103864653A (zh) * 2012-12-10 2014-06-18 韩冰 一类降低眼压的化合物及其用途
PT3811943T (pt) 2013-03-15 2023-03-15 Aerie Pharmaceuticals Inc Composto para uso no tratamento de distúrbios oculares
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
CN109640966A (zh) 2016-08-31 2019-04-16 爱瑞制药公司 眼用组合物
SG11201908179UA (en) 2017-03-31 2019-10-30 Aerie Pharmaceuticals Inc Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020056345A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3776938A (en) * 1958-05-28 1973-12-04 S Bergstrom Dihydro-pge1
US4011262A (en) * 1972-07-13 1977-03-08 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins of the two series
DD118856A5 (tr) * 1972-11-08 1976-03-20
US4024179A (en) * 1972-11-08 1977-05-17 Pfizer Inc. Substituted ω-pentanorprostaglandins
IL50310A (en) * 1972-11-08 1977-08-31 Pfizer Dimethyl ketophosphonates
JPS5720305B2 (tr) * 1973-02-28 1982-04-27
DE2365101A1 (de) * 1973-12-21 1975-07-10 Schering Ag Neue prostansaeurederivate und verfahren zu ihrer herstellung
DE2460990A1 (de) * 1974-12-21 1976-07-01 Hoechst Ag Neue prostaglandin-analoga und verfahren zu ihrer herstellung
GB1507211A (en) * 1975-02-14 1978-04-12 Ono Pharmaceutical Co Prostaglandin analogues
GB1506817A (en) * 1975-03-31 1978-04-12 Upjohn Co Prostaglandins
DE2517771A1 (de) * 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
US4051238A (en) * 1976-06-03 1977-09-27 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
DE2737808A1 (de) * 1976-08-27 1978-03-16 Pfizer 2-substituierte aryl-heterocyclische omega-pentanorprostaglandine
US4206151A (en) * 1978-12-21 1980-06-03 American Cyanamid Company 15-Deoxy-16-hydroxy-16-vinyl or cyclopropyl prostan-1-ols of the E, A and F series
JPS5829710A (ja) * 1981-03-25 1983-02-22 ジ・アツプジヨン・カンパニ− Ｐｇ類による骨孔症の治療
US4621100A (en) * 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
CA1324129C (en) * 1987-04-30 1993-11-09 Ryuzo Ueno Prostaglandins of the f series
US5166178B1 (en) * 1987-09-18 1998-07-21 R Tech Ueno Ltd Ocular hypotensive agents
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ES2062102T5 (es) * 1988-09-06 2004-12-01 Pharmacia Ab Derivados de prostaglandinas para el tratamiento de glaucoma o hipertension ocular.
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
TW249226B (tr) * 1990-04-04 1995-06-11 Aderk Ueno Kk
US5302617A (en) * 1990-04-27 1994-04-12 Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US5409911A (en) * 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
US5834498A (en) * 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5332730A (en) * 1992-10-16 1994-07-26 Allergan, Inc. Azido derivatives of cyclopentane heptanoic or heptenoic acid
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6169111B1 (en) * 1995-06-07 2001-01-02 Alcon Laboratories, Inc. Conformationally rigid aryl prostaglandins for use in glaucoma therapy
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US5703108A (en) * 1996-02-28 1997-12-30 Pfizer Inc. Bone deposition by certain prostaglandin agonists
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
CN102126998B (zh) * 1996-06-10 2013-06-12 苏坎波公司 内皮素拮抗剂
DE69714274T3 (de) * 1996-09-17 2006-06-01 Asahi Glass Co., Ltd. Fluorierte prostaglandinderivate und medikamente
US6353000B1 (en) * 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
WO1998020881A1 (en) * 1996-11-12 1998-05-22 Alcon Laboratories, Inc 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
AU725677B2 (en) * 1997-05-09 2000-10-19 Mount Sinai School Of Medicine Of The City University Of New York, The 8-iso-prostaglandins for glaucoma therapy
DE69809268T2 (de) * 1997-09-09 2003-08-28 The Procter & Gamble Co., Cincinnati Aromatische c16-c20-substituierte tetrahydro-prostaglandine und ihre verwendung als prostaglandin f agonisten

Also Published As

Publication number Publication date
JP2010254705A (ja) 2010-11-11
US6048895A (en) 2000-04-11
AU731032B2 (en) 2001-03-22
CN1269784A (zh) 2000-10-11
HUP0004427A3 (en) 2001-09-28
BR9812631A (pt) 2000-08-22
NO20001139L (no) 2000-05-04
CA2303801A1 (en) 1999-03-18
SK3382000A3 (en) 2000-10-09
HUP0004427A2 (hu) 2001-05-28
IL134840A0 (en) 2001-05-20
EP1012137A1 (en) 2000-06-28
NO20001139D0 (no) 2000-03-06
DK1012137T3 (da) 2003-03-10
KR20010023838A (ko) 2001-03-26
DE69809268T2 (de) 2003-08-28
ZA988232B (en) 1999-03-09
CO4970733A1 (es) 2000-11-07
AU9224098A (en) 1999-03-29
JP5330324B2 (ja) 2013-10-30
DE69809268D1 (de) 2002-12-12
NZ503738A (en) 2001-05-25
JP2001515885A (ja) 2001-09-25
CA2303801C (en) 2005-05-10
ATE227266T1 (de) 2002-11-15
JP4619531B2 (ja) 2011-01-26
WO1999012898A1 (en) 1999-03-18
ID24845A (id) 2000-08-24
AR017078A1 (es) 2001-08-22
EP1012137B1 (en) 2002-11-06
PE123099A1 (es) 2000-02-02
PL339221A1 (en) 2000-12-04

Similar Documents

Publication Publication Date Title
TR200000671T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20-ikameli tetrahidro prostaglandinler.
TR200000673T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
TR200000670T2 (tr) FP agonistleri olarak yararlı aromatik C16-C20- ikameli tetrahidro prostaglandinler.
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
EA200100135A1 (ru) Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов
EA200100553A1 (ru) Замещенные бициклические производные, полезные в качестве противораковых агентов
EP0896533A4 (en) PENTAFLUOROBENZEN SULPHONAMIDES AND ANALOGS
TR200003478T2 (tr) Antikanser maddeleri olarak faydalı izotiyazol türevleri
ES542321A0 (es) Un procedimiento para la preparacion de derivados de la 2 pirimidinil-1-piperazina
TR200002971T2 (tr) İkameli pirolidin hidroksamat metaloproteaz inhibitörleri
TR199901468T2 (tr) Alfa-2 adrenoseptör agonistleri olarak yararli guanidinil heterosikl bilesikleri.
ES2202156T3 (es) Nuevos analogos de 2-descarboxi-2-fosfinico prostaglandina f.
BR0008778A (pt) Análogos de prostaglandinas seletivos para fpc16 insaturados
BR0008776A (pt) Análogos de prostaglandinas fp-seletivosinsaturados c16
TR200002808T2 (tr) İlaç olarak yararlı C11 oksimil ve hidroksilamino prostaglandinleri
TR199901486T2 (tr) Alfa-2 adrenoseptör agonistleri olarak yararli 2-imidazolinilamino-benzoksazol bilesikleri.
IL166103A0 (en) Pyrrolidine derivatives and their use
BR9909268A (pt) C11 oximil e hidroxilamino prostaglandinas úteis como agonistas de fp
NO176097C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive substituerte cykloheksener
FI910159A0 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 9a-hydroxi-3-oxo-4,24(25)-stigmastadien-26 -syraderivat.
TR199901467T2 (tr) Alfa-2 adrenoseptör agonistleri olarak yararli guanidinilamino heterosikl bilesikleri.
TR199901542T2 (tr) Alfa-2 adrenoseptör agonistleri olarak yararli 2-imidazolinilaminoindazol bilesikleri.
MX9603316A (es) (+)-liarozol enantiomericamente puro.
CA2241788A1 (fr) Nouveaux derives de n-(arylsulfonyl)aminoacides, leur procede de preparation et compositions pharmaceutiques en contenant